IGF-1 DES (Des(1-3)IGF-1) is a truncated form of insulin-like growth factor-1 lacking the first three N-terminal amino acids (Gly-Pro-Glu). This modification significantly enhances potency because the tripeptide extension in full-length IGF-1 is responsible for binding to IGF binding proteins (IGFBPs). Without these amino acids, IGF-1 DES has greatly reduced IGFBP binding affinity, resulting in higher bioavailability and more potent biological activity. The peptide is approximately 10 times more potent than regular IGF-1 for stimulating muscle cell proliferation and differentiation. IGF-1 DES is particularly popular in research focused on localized muscle growth.
| Research Status | Research chemical |
|---|---|
| Half-Life | 20-30 minutes |
| Administration | Intramuscular (site-specific) |
| Typical Dosage | 50-150 mcg (site-specific) |
| Molecular Weight | 7,365 Da |
| Molecular Formula | C331H512N94O101S7 |
Binds IGF-1 receptor with greatly reduced binding protein affinity for enhanced bioactivity.
All information is presented for Research Use Only (RUO). Not medical advice.